Toggle navigation
Home
Search
Services
Blog
Contact
About
Preclinical Efficacy and Intermediate Endpoint Assays
Search grants from
Share this grant:
:
:
Abstract
Funding
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Center for Genomic and Phenomic Studies in Autism
Biological Rhythms of Reproductive Hormones and Neurotransmitters
Steroid and Retinoid Modulation of the Enkephalin Gene
Liposomal Doxorubicin with/Without Bleomycin & Vincristine for AIDS
Studies of Intermediates in Apolipoprotein B Biogenesis
Recently added grants:
Credentialing Delta-like 3 (DLL3) as an oncoprotein and immunotherapeutic target in neuroblastoma
Enhancing Physical Activity Adoption and Maintenance in Adults with Obesity by Understanding Motivation for Exercise: A Mixed Methods Research Design
Protein Arginine Methylation in Chemotherapy Resistance
Multiscale microscope for 3D cancer imaging in model organisms and organoids
Role of VGLL1 in human placental development and trophoblast specification
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN53300-4-0-1
Application #
7587180
Study Section
Project Start
2005-08-15
Project End
2009-08-14
Budget Start
Budget End
Support Year
Fiscal Year
2007
Total Cost
Indirect Cost
Related projects
NIH 2008
N01 CA
Preclinical Efficacy and Intermediate Endpoint Assays
/ University of Oklahoma Health Sciences Center
$1,535,783
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Endpoint Assays
Roa, C. /
$1,444,000
NIH 2007
N01 CA
Preclinical Efficacy and Intermediate Endpoint Assays
/
Comments
Be the first to comment on this grant